Press Releases

2012-02-02
Affibody AB and Creative Antibiotics AB enter collaboration to develop targeted antibiotics.
Solna, February 2, 2012. Affibody AB today signed an agreement with Creative Antibiotics AB with the aim of developing pharmaceutical candidates targeting gram negative bacteria.

2011-12-20
Affibody AB and Nuclisome AB to Develop Cancer Therapeutics
Solna, Sweden, December 20, 2011. Affibody AB today announced a collaboration agreement with Nuclisome AB with the aim of developing new cancer therapeutics.

2011-12-09
First-in-Human Whole-Body HER2-Receptor Mapping Using Affibody Molecular Imaging with ABY-025
Solna, Sweden, December 9, 2011. Affibody is pleased to announce that clinical imaging data using anti-HER2 Affibody® molecules have been presented at the 34th San Antonio Breast Cancer Symposium in San Antonio, USA (http://www.sabcs.org/).

2011-11-22
Notice of Extraordinary General Meeting
Kallelse till extra bolagsstämma

2011-10-26
Interim Report – January to September 2011
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the first nine months of 2011.

2011-09-19
Affibody appoints Dr. Fredrik Frejd as VP Research
Stockholm, September 19, 2011

2011-09-09
Affibody AB and GE Healthcare Expands its Relationship in the Field of Large-scale Affinity Purification
STOCKHOLM, Sweden, September 9, 2011 - Affibody AB and GE Healthcare, a division of the General Electric Company, has today expanded its relationship in the field of large-scale affinity purification.

2011-08-09
Interim Report – January to June 2011
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the First Half of 2011.

2011-06-13
Affibody to Present at Next Generation Protein Therapeutics Summit in San Francisco
Affibody AB will give a presentation titled “From Clinical Imaging to Serum Half-life Extension Using HER2-Specific Affibody Molecules” at Next Generation Protein Therapeutics Summit, taking place June 20-22, 2011 in San Francisco, California.

2011-05-05
Interim Report – January to March 2011
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the First Quarter 2011.

2011-05-04
Algeta ASA obtains licenses to develop cancer therapeutics based on Affibody® technology for two oncology targets
Affibody AB today signed a license and collaboration agreement with Algeta ASA (OSE: ALGETA) with the aim of developing new tumor-targeting alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227.

2011-03-03
Year-End Report 2010
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Year-End Report for 2010.

2011-01-05
Affibody to Present at CHI's 10th Annual PepTalk in San Diego
Affibody AB will give a presentation titled “Engineering of the Albumin Binding Domain (ABD) for Half-life Extension Applications” at CHI's 10th Annual PepTalk 2011, taking place January 10-14, 2011 in San Diego, California.